Alnylam Pharmaceuticals Reiterats 2024 Financial Guidance, Including Combined Net Product Revenues Of $1.4B-$1.5B
Author: Benzinga Newsdesk | May 02, 2024 08:03am
2024 Financial Guidance
Full year 2024 financial guidance is reiterated as follows:
Combined net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO1
$1,400 million - $1,500 million
Net Product Revenue Growth vs. 2023 at reported FX rates1
13% to 21%
Net Product Revenue Growth vs. 2023 at CER*
13% to 21%
Net revenues from collaborations and royalties
$325 million - $425 million
GAAP R&D and SG&A expenses
$1,900 million - $2,050 million
Non-GAAP R&D and SG&A expenses2
$1,675 million - $1,775 million
1 Uses January 31, 2024 FX rates including: 1 EUR = 1.08 USD and 1 USD = 147 JPY
2 Primarily excludes $225 - $275 million of stock-based compensation expense from estimated GAAP R&D and SG&A expenses
*CER = Constant Exchange Rate, representing growth calculated as if the exchange rates had remained unchanged from those used in the twelve months ended December 31, 2023. CER is a Non-GAAP measure.
